JP2018500390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500390A5 JP2018500390A5 JP2017549860A JP2017549860A JP2018500390A5 JP 2018500390 A5 JP2018500390 A5 JP 2018500390A5 JP 2017549860 A JP2017549860 A JP 2017549860A JP 2017549860 A JP2017549860 A JP 2017549860A JP 2018500390 A5 JP2018500390 A5 JP 2018500390A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- wnt5a
- tumor
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 101150109862 WNT-5A gene Proteins 0.000 claims 10
- 102000043366 Wnt-5a Human genes 0.000 claims 10
- 108700020483 Wnt-5a Proteins 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 208000032612 Glial tumor Diseases 0.000 claims 5
- 206010018338 Glioma Diseases 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 2
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 101150051240 DLX2 gene Proteins 0.000 claims 1
- 102000051096 EphA2 Receptor Human genes 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100035441 FRAS1-related extracellular matrix protein 2 Human genes 0.000 claims 1
- 101710168206 FRAS1-related extracellular matrix protein 2 Proteins 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 231100000673 dose–response relationship Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090029P | 2014-12-10 | 2014-12-10 | |
| US62/090,029 | 2014-12-10 | ||
| PCT/IB2015/002577 WO2016092378A1 (en) | 2014-12-10 | 2015-12-09 | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500390A JP2018500390A (ja) | 2018-01-11 |
| JP2018500390A5 true JP2018500390A5 (enExample) | 2019-01-24 |
| JP6921755B2 JP6921755B2 (ja) | 2021-08-18 |
Family
ID=55353245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549860A Active JP6921755B2 (ja) | 2014-12-10 | 2015-12-09 | 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10688167B2 (enExample) |
| EP (1) | EP3229831B1 (enExample) |
| JP (1) | JP6921755B2 (enExample) |
| KR (1) | KR102674191B1 (enExample) |
| AU (1) | AU2015359043C1 (enExample) |
| CA (1) | CA2970140A1 (enExample) |
| DK (1) | DK3229831T3 (enExample) |
| ES (1) | ES2796973T3 (enExample) |
| WO (1) | WO2016092378A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10852069B2 (en) | 2010-05-04 | 2020-12-01 | Fractal Heatsink Technologies, LLC | System and method for maintaining efficiency of a fractal heat sink |
| ES2796973T3 (es) * | 2014-12-10 | 2020-11-30 | Hyperstem Sa | Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales |
| CN111417403B (zh) * | 2017-10-25 | 2024-06-04 | 温特研究公司 | Wnt5a肽在减少癌症干细胞中的作用 |
| KR101921836B1 (ko) | 2017-11-23 | 2018-11-26 | 서울대학교병원 | 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트 |
| WO2019207512A2 (en) * | 2018-04-24 | 2019-10-31 | Universidade Do Minho | A novel oncogene biomarker, method and uses thereof |
| EP3613757A1 (en) * | 2018-08-20 | 2020-02-26 | Wntresearch AB | Solution phase routes for wnt hexapeptides |
| EP3666789A1 (en) * | 2018-12-14 | 2020-06-17 | Wntresearch AB | Linear solution phase routes for wnt hexapeptides |
| CA3137093A1 (en) * | 2019-04-16 | 2020-10-22 | Wntresearch Ab | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer |
| WO2021034784A1 (en) | 2019-08-16 | 2021-02-25 | Poltorak Technologies, LLC | Device and method for medical diagnostics |
| CN114081954B (zh) * | 2021-10-30 | 2023-02-28 | 中国人民解放军陆军军医大学第一附属医院 | 用于胶质母细胞瘤治疗的药物组合物以及预后的诊断试剂 |
| WO2025088835A1 (ja) * | 2023-10-25 | 2025-05-01 | 国立大学法人大阪大学 | ヒト化抗ｃｋａｐ４抗体又はその抗原結合性断片 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| AT396872B (de) | 1985-07-30 | 1993-12-27 | Glaxo Group Ltd | Gerät zur verabreichung von medikamenten in pulverform |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP1226172A1 (en) * | 1999-11-05 | 2002-07-31 | Forskarpatent i Syd AB | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
| DK2384763T3 (en) * | 2005-05-30 | 2015-07-20 | Wntres Ab | Peptide ligand for disrupting cancer cell migration |
| ES2527454T3 (es) * | 2008-08-13 | 2015-01-23 | Wntresearch Ab | El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico |
| AU2011205409B2 (en) * | 2010-01-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Wnt-binding agents and uses thereof |
| EP2446895A1 (en) | 2010-10-01 | 2012-05-02 | Stemgen S.P.A. | EPH receptor expression in tumor stem cells |
| PL2726880T3 (pl) * | 2011-07-01 | 2019-09-30 | Wntresearch Ab | Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty |
| US20140171356A1 (en) | 2012-12-12 | 2014-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically immobilized wnt protein and methods of use |
| ES2796973T3 (es) * | 2014-12-10 | 2020-11-30 | Hyperstem Sa | Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales |
-
2015
- 2015-12-09 ES ES15834638T patent/ES2796973T3/es active Active
- 2015-12-09 US US15/533,842 patent/US10688167B2/en active Active
- 2015-12-09 CA CA2970140A patent/CA2970140A1/en active Pending
- 2015-12-09 EP EP15834638.7A patent/EP3229831B1/en active Active
- 2015-12-09 AU AU2015359043A patent/AU2015359043C1/en active Active
- 2015-12-09 DK DK15834638.7T patent/DK3229831T3/da active
- 2015-12-09 JP JP2017549860A patent/JP6921755B2/ja active Active
- 2015-12-09 KR KR1020177018938A patent/KR102674191B1/ko active Active
- 2015-12-09 WO PCT/IB2015/002577 patent/WO2016092378A1/en not_active Ceased
-
2020
- 2020-05-13 US US15/931,081 patent/US11357840B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500390A5 (enExample) | ||
| Mu et al. | Hypoxia-stimulated mesenchymal stem cell-derived exosomes loaded by adhesive hydrogel for effective angiogenic treatment of spinal cord injury | |
| Luo et al. | Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension | |
| Ramer et al. | Restoring function after spinal cord injury: towards clinical translation of experimental strategies | |
| Shi et al. | Collagen scaffolds modified with collagen-binding bFGF promotes the neural regeneration in a rat hemisected spinal cord injury model | |
| JP2020040969A5 (enExample) | ||
| Kim et al. | Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration | |
| SA521421559B1 (ar) | أجهزة قابلة للزرع للعلاج بالخلايا وطرق ذات الصلة | |
| Hannan et al. | Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve‐injured rats | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| KR101749138B1 (ko) | 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도 | |
| Luksik et al. | The role of immune checkpoint inhibition in the treatment of brain tumors | |
| KR20190120197A (ko) | 치료 및 신경보호 펩티드 | |
| Ji et al. | Decellularized matrix of adipose-derived mesenchymal stromal cells enhanced retinal progenitor cell proliferation via the Akt/Erk pathway and neuronal differentiation | |
| Smith et al. | Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats | |
| EP2563379A1 (en) | Sox9 inhibitors | |
| JP6841871B2 (ja) | 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物 | |
| CN106222173A (zh) | circRNA MNCR核苷酸、含有该核苷酸的药物组合物及其用途 | |
| CN113677371A (zh) | 唾液腺再生 | |
| Hettiaratchi et al. | Recent advances in regenerative medicine approaches for spinal cord injuries | |
| KR102007872B1 (ko) | 줄기세포를 멜라토닌 처리 하여 증식 촉진 또는 생존율을 증가시키는 방법 | |
| NZ732532A (en) | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors | |
| NZ732532B2 (en) | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors | |
| Omar Khudhur et al. | Epothilone B loaded in acellular nerve allograft enhanced sciatic nerve regeneration in rats | |
| MX2021007410A (es) | Proteina de fusion que comprende variantes de la proteina lefty a humana y el uso de estas. |